基本信息
浏览量:103
职业迁徙
个人简介
He has acquired long-standing experience in molecular biology, regulation of gene expression and of genome stability by DNA methylation. He is internationally recognized leader in the field of research on Trop molecules. His research group has cloned the genes, biochemically and functionally characterized Trop-1/EpCAM and Trop -2 as stimulators of tumor cell growth and metastatic spreading.
Major recent achievements include the generation of Trop-1 knock out mice, and demonstration of induction of tufting enteropathy genetic disease. This was shown to occur through disruption of E-cadherin-locked cell-cell junctions.
Additional achievements bear to the function of cell-cell adhesion molecules in signal transduction, cancer invasion and metastasis, and to the discovery that p53 regulates DNA methylation and subsequent genome stability. This was extended to the study of the prognostic / predictive relevance of the markers above in human breast cancer. Major achievements include demonstration of the impact of breast cancer lymph node nanometastases on prognosis. Additional newly-developed prognostic markers include Trop-1/EpCAM, E-cadherin/ß-catenin, PLCγ, Topoisomerase IIα, 90k, p53 in triple negative breast cancer, tumor Trop-2 and circulating Trop-2. Saverio Alberti’ scientific experience includes next-generation sequencing, DNA array and proteome analysis.
Saverio Alberti is founder / president of two biotech companies, Oncoxx Biotech and Mediterranea Theranostic, whose mission is to develop proprietary anti-cancer therapies and diagnostics. Saverio Alberti holds 14 patent families/ 33 patents on cancer therapeutics and biotech applications to cancer diagnosis. Eight of them have received approval as PCT in the US and EU. His research group has developed dedicated software for the identification of fusion oncogenes and of transcription factors binding sites.
Major recent achievements include the generation of Trop-1 knock out mice, and demonstration of induction of tufting enteropathy genetic disease. This was shown to occur through disruption of E-cadherin-locked cell-cell junctions.
Additional achievements bear to the function of cell-cell adhesion molecules in signal transduction, cancer invasion and metastasis, and to the discovery that p53 regulates DNA methylation and subsequent genome stability. This was extended to the study of the prognostic / predictive relevance of the markers above in human breast cancer. Major achievements include demonstration of the impact of breast cancer lymph node nanometastases on prognosis. Additional newly-developed prognostic markers include Trop-1/EpCAM, E-cadherin/ß-catenin, PLCγ, Topoisomerase IIα, 90k, p53 in triple negative breast cancer, tumor Trop-2 and circulating Trop-2. Saverio Alberti’ scientific experience includes next-generation sequencing, DNA array and proteome analysis.
Saverio Alberti is founder / president of two biotech companies, Oncoxx Biotech and Mediterranea Theranostic, whose mission is to develop proprietary anti-cancer therapies and diagnostics. Saverio Alberti holds 14 patent families/ 33 patents on cancer therapeutics and biotech applications to cancer diagnosis. Eight of them have received approval as PCT in the US and EU. His research group has developed dedicated software for the identification of fusion oncogenes and of transcription factors binding sites.
研究兴趣
论文共 226 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Valentina Giansante, Luca Di Angelo, Chiara Calabrese, Paolo De Sanctis,Paolo Regi, Filippo Maria Martelli,Gianmarco Stati,Rossano Lattanzio,Saverio Alberti,Emanuela Guerra,Roberta Di Pietro
Marco Trerotola,Valeria Relli,Romina Tripaldi,Pasquale Simeone,Emanuela Guerra, Andrea Sacchetti,Martina Ceci,Ludovica Pantalone, Paolo Ciufici,Antonino Moschella,Valeria Caiolfa,Moreno Zamai,
biorxiv(2024)
FRONTIERS IN GENETICS (2024): 1297367-1297367
Cancer Researchno. 6_Supplement (2024): 2608-2608
Saverio Alberti,Emanuela Guerra,Antonino Moschella,Martina Ceci, Ludovica Pantalone,Roberta Di Pietro,Marco Trerotola
Cancer Researchno. 6_Supplement (2024): 346-346
Frontiers in oncology (2023): 1151090
Valentina Giansante,Gianmarco Stati,Silvia Sancilio,Emanuela Guerra,Saverio Alberti,Roberta Di Pietro, Joerg D. Hoheisel
Tania Pannellini,Manuela Iezzi, Marcella Liberatore,Federica Sabatini,Stefano Iacobelli,Cosmo Rossi,Saverio Alberti, Carmine Di Ilio,Paola Vitaglione,Vincenzo Fogliano,Mauro Piantelli
crossref(2023)
CANCER RESEARCHno. 7 (2023)
引用0浏览0引用
0
0
CANCER RESEARCHno. 7 (2023): 6310-6310
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn